Triple Agonism · GLP-1/GIP/Glucagon · Method Review

Triple-Agonist Peptides (GLP-1/GIP/Glucagon): how triple agonism works, and the retatrutide benchmark

Q: What is a triple-agonist peptide?

A triple-agonist peptide is a single engineered peptide that switches on three metabolic hormone receptors at once — the GLP-1, GIP and glucagon receptors. Instead of a cocktail of separate drugs, one molecule carries three coordinated jobs. Retatrutide is the best-known example, a GLP-1/GIP/glucagon triagonist studied for obesity and type 2 diabetes.

Q: How does triple agonism work?

Each of the three hormone arms does a different job: the GLP-1 arm drives glucose-dependent insulin release and lowers appetite; the GIP arm adds an insulin-sensitising and appetite effect; and the glucagon arm raises energy expenditure and helps mobilise liver fat. Because glucagon can raise blood sugar on its own, its potency is deliberately balanced against the two incretin arms so the net effect lowers glucose while burning more energy. All three activities travel together on one molecule.

Q: Why is the retatrutide benchmark important?

In a published phase 2 obesity trial, the GLP-1/GIP/glucagon triagonist retatrutide produced the largest mean weight reduction reported for a single metabolic agent at the time — around 24 percent of body weight at the highest dose over 48 weeks. That makes the triple-agonist class the strongest weight-loss data class studied so far, and the reference point every newer metabolic peptide is measured against. Nothing here is medical advice.

Q: What is the hardest part of designing a triple agonist?

Balance. A triagonist is only useful if it hits each of the three receptors with the right relative strength — too much glucagon and blood sugar rises, too little and the energy-expenditure benefit is lost. Tuning three receptor potencies, plus half-life and manufacturability, into one amino-acid sequence — and then keeping that engineered chain intact through drying and storage — is the real challenge. Nothing here is medical advice.

Bogdan Dicoias¹ — Inventor, Panacea Bio Chem

¹Panacea Bio Chem Ltd, United Kingdom · correspondence via panaceabiochem.co.uk

Preprint — not peer-reviewed Posted 05 Jul 2026 Ref PBC-PP-2026-RETTA Type Method review Field Metabolic peptide pharmacology

A molecular model of the metabolic-peptide class behind triple agonism (GLP-1/GIP/glucagon) — a triple-agonist peptide explainer by Panacea Bio Chem and Bogdan Dicoias — A molecular model standing in for the metabolic-peptide class behind **triple agonism** — one engineered chain built to switch on three hormone receptors at once (GLP-1, GIP and glucagon). Explainer by Panacea Bio Chem and **Bogdan Dicoias**.

Abstract

A triple-agonist peptide is a single engineered molecule that switches on three metabolic hormone receptors at once — GLP-1, GIP and glucagon. Where earlier medicines pressed one metabolic button (GLP-1 alone) or two (the GIP/GLP-1 dual agonist tirzepatide⁴), a triagonist presses all three, with each arm doing a distinct job and their strengths deliberately balanced into one sequence. The class produced the strongest weight-loss data reported for a single metabolic agent: in a published phase 2 obesity trial the triagonist retatrutide reached roughly a 24% mean reduction in body weight¹ at 48 weeks. This preprint explains, in plain language, how triple agonism works, why the retatrutide benchmark matters, and where Panacea Bio Chem works: designing balanced multi-receptor metabolic chains — and keeping an engineered chain intact all the way to the patient.

Keywords: triple agonist peptide · triple agonism · GLP-1/GIP/glucagon · triagonist · retatrutide · GIP receptor agonist · glucagon receptor agonist · incretin · unimolecular multi-agonist · metabolic peptide

1. Introduction — three hormones, one chain

The body does not manage weight and blood sugar with a single lever. A committee of gut and pancreatic hormones — GLP-1, GIP, glucagon, amylin and others — works in concert after every meal, and nudging just one of them often lets the rest quietly compensate. That is why the first metabolic medicines, which activated the GLP-1 receptor alone, went so far and no further.

A triple agonist answers with a different idea: build one peptide that turns three of those locks at once. The GLP-1 arm drives glucose-dependent insulin release and dampens appetite; the GIP arm adds its own insulin and appetite effects; and the glucagon arm raises energy expenditure and helps the liver mobilise fat. Three coordinated actions travel together on one molecule instead of drifting apart the way a cocktail of separate drugs would.

This is not a thought experiment — it is the mechanism behind the most striking metabolic results of the decade. The progression is easy to name and hard to build: mono → dual → triple agonist, each rung adding one more receptor to the same chain. The triple rung is where the numbers became remarkable, and where the design difficulty became real.

2. What each of the three arms actually does

GLP-1, GIP and glucagon — three jobs on one molecule

The three hormones a triagonist targets are structural cousins from one ancestral family⁵, which is exactly why a single carefully engineered chain can be nudged to fit all three of their receptors. But their jobs differ, and that division of labour is the whole point of combining them:

Arm	Receptor	What it contributes
GLP-1	GLP-1R	Glucose-dependent insulin release; slows gastric emptying; central appetite suppression
GIP	GIPR	Adds insulin sensitisation and its own appetite/nausea-tolerance effects that complement GLP-1
Glucagon	GCGR	Raises energy expenditure; mobilises liver fat — the arm that burns fuel rather than only curbing intake

The subtlety is the glucagon arm. On its own, glucagon raises blood sugar — it is the hormone that tells the liver to release glucose. Putting it into a metabolic medicine sounds backwards. The resolution is balance: the glucagon potency is tuned low enough, and the two incretin arms strong enough, that the net effect still lowers glucose while the glucagon arm quietly turns up energy expenditure. Get that ratio wrong and the molecule works against itself.

3. How a triple agonist is built

Designing a triagonist is an exercise in deliberate compromise, run roughly like this:

Start from the shared backbone — GLP-1, GIP and glucagon already resemble one another, so one chain can plausibly address all three receptors.
Graft the recognition points — splice in the residues each receptor needs to see, building a chimeric sequence that carries signals for GLP-1R, GIPR and GCGR.
Tune the three-way balance — adjust individual amino acids until each receptor is hit with the intended relative strength, keeping the glucagon arm offset by the incretin arms. This is the crux.
Extend the half-life — attach a fatty-acid chain so the peptide rides on blood proteins and lasts long enough to dose weekly rather than hourly.
Test, and re-balance — measure activity at all three receptors, then loop back, because improving one target usually disturbs another.

A triagonist is not the strongest key for any one lock — it is one key deliberately cut to open three, with the glucagon arm held in careful check by the other two.

4. The retatrutide benchmark — the strongest weight-loss data class

Why does the triple class matter beyond elegance? Because it set the number everyone else is now measured against. In a published phase 2 obesity trial, the GLP-1/GIP/glucagon triagonist retatrutide¹ produced the largest mean weight reduction reported for a single metabolic agent at the time — around 24% of body weight at the highest dose over 48 weeks, with weight still falling when the study ended. A separate phase 2 trial in type 2 diabetes showed parallel improvements in blood sugar². For context, the table places the rungs side by side using representative published figures:

Rung	Receptors engaged	Representative peptide	Order-of-magnitude weight effect*
Mono-agonist	GLP-1	Semaglutide	~15%
Dual agonist	GIP + GLP-1	Tirzepatide	~21%
Triple agonist	GLP-1 + GIP + glucagon	Retatrutide	~24% (phase 2)

*Illustrative mean values from separate published trials of different design and duration, placed together only to show the direction of travel — not head-to-head comparisons.

Two cautions belong next to that number. First, phase 2 is a mid-stage read, not a final verdict; larger and longer phase 3 programmes are what settle a medicine's place. Second, more receptors means more to balance and more to watch, from nausea to the glucagon arm's effect on glucose. The benchmark is a frontier marker, not a finish line — which is exactly why the design of the class, not just its headline figure, is where the interesting work sits.

The benchmark by evidence class

The figures above travel better with their provenance attached. This table classes every retatrutide result cited on this page — and the wider programme standing behind it — by where the record actually lives: a peer-reviewed journal primary or a trial-registry entry. Registry states are as observed on ClinicalTrials.gov on 2026-09-05.

Figure	Date	Trial registry id	Phase	Results posted to registry	Source class
~24% mean weight reduction at 48 weeks (highest dose), obesity¹	2023-08-10	NCT04881760 (completed 2022-11-22, n=338)	Phase 2	Yes	Journal primary — N Engl J Med 2023 (PMID 37366315)
Phase 2 improvements in type 2 diabetes²	2023-08-12	NCT04867785 (completed 2022-10-27, n=281)	Phase 2	Yes	Journal primary — Lancet 2023 (PMID 37385280)
Discovery to clinical proof of concept (LY3437943)³	2022-09-06	—	Proof of concept	—	Journal primary — Cell Metab 2022 (PMID 35985340)
Phase 3 programme: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4	observed 2026-09-05	NCT05929066 · NCT05929079 · NCT05882045 · NCT05931367 (completed 2025-11-14 to 2026-06-16)	Phase 3	No, as of 2026-09-05	Registry record; no peer-reviewed result observed
Retatrutide vs tirzepatide head-to-head (ongoing)	observed 2026-09-05	NCT06662383 (completion estimated 2026-12)	Phase 3	No, as of 2026-09-05	Registry record; ongoing

A completed trial is not a posted result, and a posted result is not a peer-reviewed publication — the classes above are kept separate on purpose. Company topline figures for the phase 3 programme circulate in the press and disagree with each other; none is restated here until the primary company sources are on file. Re-checked quarterly.

One name note: Rettaglutide, this site's namesake, is Panacea Bio Chem's design line — it is not retatrutide, the Eli Lilly triple agonist (LY3437943) whose published results set the benchmark above; the names differ by two letters and refer to entirely separate things.

5. Where Panacea Bio Chem works — the balanced-chain frontier

Building one engineered chain that speaks to three receptors in balance — and then surviving intact into a usable dose — is precisely the ground Panacea Bio Chem treats as its focus. Panacea builds custom amino-acid chains to purpose, and reads the triple-agonist problem as two coupled challenges: getting the balance of the three receptor activities right in the sequence, and then keeping that engineered, acylated, often non-natural chain intact through synthesis, drying, storage and reconstitution. Its ongoing work explores proprietary methods aimed at exactly those failure modes:

TgShift™ raises the working glass-transition temperature →, so a fragile multi-target chain sets into a stable glass instead of collapsing during drying.
Cryolapse™ freeze-dries gently, without surfactants →, so an engineered sequence dries without the shear and flash-boiling that unpick delicate folds.
RedoxVault™ keeps the dried peptide oxygen-starved and metal-isolated, so storage does not chemically erode a hard-won sequence.
All of it watched in real time by S3Pulse™, the biointegrity algorithm →.

The exact sequences, receptor-balance strategies, parameters and hardware that make this work repeatable remain proprietary to Panacea Bio Chem — the outline is here; the recipe stays behind the door.

Within triple-agonist design, Panacea Bio Chem's own line of work — carried under the name Rettaglutide — approaches the balanced GLP-1/GIP/glucagon chain as a research direction. The specific targets, sequence strategy, receptor ratio and balancing method are held by Bogdan Dicoias and treated as; they are not disclosed on this page, and nothing here states a clinical claim on his behalf. What is stated is the direction: one carefully balanced molecule, three coordinated arms, and the same insistence on a chain that survives intact to the point of use.

A peptide laboratory where custom metabolic peptides are synthesised — the setting behind triple-agonist design, a Panacea Bio Chem explainer by Bogdan Dicoias — The quiet half of the work: a peptide laboratory, where a designed **triple-agonist** chain is synthesised and then preserved so its tuned three-receptor balance survives into a usable dose. Explainer by Panacea Bio Chem, **Bogdan Dicoias**.

6. The story — GIP, the incretin that came in from the cold

Triple agonism has a quieter origin story than the lizard-venom tale usually told about GLP-1 — and it belongs to the middle arm, GIP. Discovered in the early 1970s, GIP (glucose-dependent insulinotropic polypeptide) was long treated as the lesser incretin: in people with type 2 diabetes its insulin-releasing effect looked blunted, and for decades the field more or less wrote it off. For a while the received wisdom even ran the opposite way — that blocking GIP might help weight, and GIP-receptor antagonists were pursued as anti-obesity candidates.

Then the data turned the story upside down. When GIP activity was deliberately added to a GLP-1 agonist, the dual GIP/GLP-1 molecule tirzepatide outperformed GLP-1 alone — the very hormone the field had dismissed turned out to amplify the benefit rather than blunt it⁶. The "GIP paradox" — the odd fact that both agonism and antagonism were argued to help — became one of metabolic medicine's most useful puzzles. Its resolution rehabilitated the forgotten incretin and opened the way to the triple: once GIP earned its place beside GLP-1, adding a measured glucagon arm to burn fuel produced the triagonist, and with it retatrutide's benchmark numbers. The molecule that came in from the cold became the middle pillar of the strongest weight-loss class yet.

7. Application fields

Triple agonism earns the most wherever a condition is run by a committee of signals rather than one — where hitting a single receptor lets the others compensate:

Obesity — the flagship use, where combined appetite suppression (GLP-1/GIP) and raised energy expenditure (glucagon) attack weight from intake and output at once.
Type 2 diabetes — glucose control from the incretin arms, with the glucagon arm balanced so blood sugar still falls.
Metabolic (fatty) liver disease — the glucagon arm's ability to mobilise liver fat is exactly the lever a GLP-1-only molecule leaves untouched, making triagonists a natural candidate here.
Cardiometabolic overlap — the tangle of blood pressure, lipids and inflammation that rides along with obesity and diabetes, whose biology spans several receptor systems.
Custom research peptides — bespoke, balanced multi-receptor chains built to order, where custom, research-grade and pharmaceutical-grade peptide synthesis meets the triple-agonist frontier.

Each of these shares a dependency the headlines skip: the more finely a molecule is balanced across three receptors, and the more acylated and non-natural its sequence, the harder it is to keep folded and intact from synthesis to dose. That dependency is the thread tying triple-agonist design back to preservation, and to Panacea's work.

Frequently asked

What is a triple-agonist peptide?
A single engineered peptide — a triagonist — that switches on three metabolic hormone receptors at once: GLP-1, GIP and glucagon. One molecule carries three coordinated jobs. Retatrutide is the best-known example.

How does triple agonism work?
Each arm does a different job: the GLP-1 arm drives glucose-dependent insulin and lowers appetite; the GIP arm adds insulin sensitisation and appetite effects; the glucagon arm raises energy expenditure and mobilises liver fat. Because glucagon can raise blood sugar alone, its potency is balanced against the two incretin arms so the net effect lowers glucose while burning more energy.

Why is the retatrutide benchmark important?
In a published phase 2 obesity trial, retatrutide produced roughly a 24% mean weight reduction at the highest dose over 48 weeks¹ (Jastreboff AM et al., N Engl J Med 2023; PMID 37366315, DOI 10.1056/NEJMoa2301972) — the largest reported for a single metabolic agent at the time. That makes the triple-agonist class the strongest weight-loss data class studied so far, and the reference point newer metabolic peptides are measured against.

What is the hardest part of designing a triple agonist?
Balance. The molecule has to hit each of the three receptors with the right relative strength — too much glucagon and blood sugar rises, too little and the energy-expenditure benefit is lost. Tuning three potencies, plus half-life and manufacturability, into one sequence — and keeping that engineered chain intact through drying and storage — is the real challenge. Nothing here is medical advice.

Trending in the field

References & further reading

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med 389, 514–526 (2023).
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, in people with type 2 diabetes: a phase 2 trial. Lancet 402, 529–544 (2023).
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab 34, 1234–1247 (2022).
Tirzepatide — a dual GIP/GLP-1 receptor agonist. Wikipedia.
Incretin hormones (GLP-1 and GIP) — the proglucagon / glucagon superfamily. Wikipedia.
Gastric inhibitory polypeptide (GIP) — biology and receptor pharmacology. Wikipedia.
Retatrutide — a triple GLP-1/GIP/glucagon receptor agonist. Wikipedia.